Importantly, dependency on CDC7 was induced following RB1 and p53 loss, and the CDC7 inhibitor, Simurosertib, synergized with EGFR and androgen receptor inhibitors in xenograft models of LUAD and prostate cancer NE transformation, respectively [57]. Here, CDC7 is linked to prostate carcinoma.